Eckert & Ziegler (EUZ) Stock Overview
Manufactures and sells isotope technology components worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 3/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for EUZ from our risk checks.
EUZ Community Fair Values
Create NarrativeSee what 16 others think this stock is worth. Follow their fair value or set your own to get alerts.
Eckert & Ziegler SE Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €17.55 |
| 52 Week High | €23.25 |
| 52 Week Low | €12.27 |
| Beta | 1.55 |
| 1 Month Change | -2.99% |
| 3 Month Change | -18.94% |
| 1 Year Change | 25.24% |
| 3 Year Change | 32.69% |
| 5 Year Change | 33.97% |
| Change since IPO | 749.19% |
Recent News & Updates
What Eckert & Ziegler SE's (ETR:EUZ) P/E Is Not Telling You
Sep 29
Do Eckert & Ziegler's (ETR:EUZ) Earnings Warrant Your Attention?
Sep 13Recent updates
What Eckert & Ziegler SE's (ETR:EUZ) P/E Is Not Telling You
Sep 29Do Eckert & Ziegler's (ETR:EUZ) Earnings Warrant Your Attention?
Sep 13The Compensation For Eckert & Ziegler SE's (ETR:EUZ) CEO Looks Deserved And Here's Why
Jun 12Eckert & Ziegler's (ETR:EUZ) Solid Earnings Have Been Accounted For Conservatively
May 20Eckert & Ziegler SE's (ETR:EUZ) P/E Is Still On The Mark Following 27% Share Price Bounce
May 08What Is Eckert & Ziegler SE's (ETR:EUZ) Share Price Doing?
Apr 19Eckert & Ziegler (ETR:EUZ) Has A Pretty Healthy Balance Sheet
Mar 17If EPS Growth Is Important To You, Eckert & Ziegler (ETR:EUZ) Presents An Opportunity
Feb 28
European GalliaPharm Approval And Telix Partnership Will Open New Markets And Strengthen Future Prospects
European market expansion via GalliaPharm approval and strategic partnerships drive new revenue streams and improved earnings potential.Eckert & Ziegler SE's (ETR:EUZ) Share Price Could Signal Some Risk
Aug 08Does Eckert & Ziegler (ETR:EUZ) Have A Healthy Balance Sheet?
Jul 17Why We Think Eckert & Ziegler SE's (ETR:EUZ) CEO Compensation Is Not Excessive At All
Jun 20Investors Met With Slowing Returns on Capital At Eckert & Ziegler (ETR:EUZ)
Jun 05Is Now An Opportune Moment To Examine Eckert & Ziegler SE (ETR:EUZ)?
May 13Eckert & Ziegler SE (ETR:EUZ) Investors Are Less Pessimistic Than Expected
Apr 27Here's Why Eckert & Ziegler (ETR:EUZ) Can Manage Its Debt Responsibly
Apr 12Slowing Rates Of Return At Eckert & Ziegler Strahlen- und Medizintechnik (ETR:EUZ) Leave Little Room For Excitement
Mar 06What Eckert & Ziegler Strahlen- und Medizintechnik AG's (ETR:EUZ) P/E Is Not Telling You
Jan 04Eckert & Ziegler Strahlen- und Medizintechnik (ETR:EUZ) Has A Pretty Healthy Balance Sheet
Dec 20Eckert & Ziegler Strahlen- und Medizintechnik (ETR:EUZ) Hasn't Managed To Accelerate Its Returns
Nov 15What Is Eckert & Ziegler Strahlen- und Medizintechnik AG's (ETR:EUZ) Share Price Doing?
Oct 01A Look At The Intrinsic Value Of Eckert & Ziegler Strahlen- und Medizintechnik AG (ETR:EUZ)
Aug 22These 4 Measures Indicate That Eckert & Ziegler Strahlen- und Medizintechnik (ETR:EUZ) Is Using Debt Reasonably Well
Jul 16Is It Time To Consider Buying Eckert & Ziegler Strahlen- und Medizintechnik AG (ETR:EUZ)?
Jun 22The Return Trends At Eckert & Ziegler Strahlen- und Medizintechnik (ETR:EUZ) Look Promising
May 17Is Eckert & Ziegler Strahlen- und Medizintechnik AG (ETR:EUZ) Potentially Undervalued?
Mar 20Eckert & Ziegler Strahlen- und Medizintechnik's (ETR:EUZ) Returns Have Hit A Wall
Jan 24We Think Eckert & Ziegler Strahlen- und Medizintechnik (ETR:EUZ) Can Stay On Top Of Its Debt
Oct 27Is It Time To Consider Buying Eckert & Ziegler Strahlen- und Medizintechnik AG (ETR:EUZ)?
Oct 05Eckert & Ziegler Strahlen- und Medizintechnik (ETR:EUZ) Has Some Way To Go To Become A Multi-Bagger
Aug 21Is Eckert & Ziegler Strahlen- und Medizintechnik (ETR:EUZ) A Risky Investment?
Jul 21Is There Now An Opportunity In Eckert & Ziegler Strahlen- und Medizintechnik AG (ETR:EUZ)?
Jun 13Eckert & Ziegler Strahlen- und Medizintechnik (ETR:EUZ) Will Pay A Larger Dividend Than Last Year At €0.50
May 13Returns At Eckert & Ziegler Strahlen- und Medizintechnik (ETR:EUZ) Are On The Way Up
May 09Eckert & Ziegler Strahlen- und Medizintechnik's (ETR:EUZ) Dividend Will Be Increased To €0.50
Apr 24Shareholder Returns
| EUZ | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 3.8% | 3.4% | -0.07% |
| 1Y | 25.2% | -4.3% | 12.1% |
Return vs Industry: EUZ exceeded the German Medical Equipment industry which returned -4.3% over the past year.
Return vs Market: EUZ exceeded the German Market which returned 12.1% over the past year.
Price Volatility
| EUZ volatility | |
|---|---|
| EUZ Average Weekly Movement | 5.3% |
| Medical Equipment Industry Average Movement | 5.7% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 12.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: EUZ has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: EUZ's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2024 | 1,098 | Harald Hasselmann | www.ezag.com |
Eckert & Ziegler SE manufactures and sells isotope technology components worldwide. It operates through two segments, Medical and Isotope Products. The company provides small implants for the treatment of prostate cancer seeds; and eye applicators based on ruthenium-106 and iodine-125 for the treatment of uveal melanomas; brain seed, HDR and brachytherapy; ophthalmological products; therapeutic and radiotherapy accessories, X-Ray therapy, GA-68 generators, radiochromatography, hot cells; and radiopharmaceuticals, laboratory equipment, radiosynthesis equipment, quality-control equipment, consumables, therapeutic products and plant engineering, and other services.
Eckert & Ziegler SE Fundamentals Summary
| EUZ fundamental statistics | |
|---|---|
| Market cap | €1.10b |
| Earnings (TTM) | €41.50m |
| Revenue (TTM) | €299.27m |
Is EUZ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EUZ income statement (TTM) | |
|---|---|
| Revenue | €299.27m |
| Cost of Revenue | €153.86m |
| Gross Profit | €145.41m |
| Other Expenses | €103.91m |
| Earnings | €41.50m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
Nov 13, 2025
| Earnings per share (EPS) | 0.66 |
| Gross Margin | 48.59% |
| Net Profit Margin | 13.87% |
| Debt/Equity Ratio | 7.4% |
How did EUZ perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/24 18:26 |
| End of Day Share Price | 2025/10/24 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Eckert & Ziegler SE is covered by 4 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Benjamin Thielmann | Berenberg |
| Adrian Kowollik | Dr. Kalliwoda Research |
| Alexander Galitsa | Hauck Aufhäuser Investment Banking |